Travels with Vignesh

Celebrating collaboration and resilience: The PRINCIPLE PANORAMIC art exhibition

21 March 2024

Celebrate the resilience and collaboration behind Oxford's groundbreaking PANORAMIC and PRINCIPLE COVID-19 trials through "The PANORAMIC PRINCIPLE" exhibition. Artist Tanya Poole's powerful portraits honour the diverse array of participants, researchers, and medical professionals whose inclusive efforts set global benchmarks and transformed lives. An inspiring tribute to human determination in the face of adversity.

New phase 3 trial data confirm the uniquely high efficacy and good safety profile of the R21/Matrix-M malaria vaccine in African children

1 February 2024

Investigators immunised over 4800 young children in a trial in Burkina Faso, Kenya, Mali and Tanzania and found on average 78% efficacy in the 5–17-month age group over the first year To date 25 million doses manufactured and ready for roll-out by The Serum Institute of India (SII) in the next three to four months

Nuffield Department of Primary Care Health Sciences set to deliver clinical trials expertise to China National Biotec Group in new collaboration

28 November 2023

The training initiative builds the foundations to explore further collaborations encompassing joint research efforts, leadership programmes, and a shared commitment to advancing clinical trials.

Oxford launches new vaccine trial to enhance design of flu & COVID-19 vaccines

26 October 2023

This study will test the responses of cells in lymph nodes before and after immunisation with flu and COVID-19 vaccines and compare reactions in older and younger adults

Oxford R21/Matrix-M™ malaria vaccine receives WHO recommendation for use paving the way for global roll-out

2 October 2023

The highly effective vaccine developed by the University of Oxford and the Serum Institute of India, leveraging Novavax’s adjuvant is critical to reducing over half a million malaria-related deaths annually.

Oxford and Liverpool scientists launch new vaccine trial for Middle East Respiratory Syndrome (MERS)

19 September 2023

The UK trial is the next step in the development of a vaccine to protect people against MERS – a deadly viral illness with no current vaccines and the potential to cause a pandemic.

First volunteers receive vaccine for Crimean-Congo haemorrhagic fever in Oxford clinical trial

13 September 2023

A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to volunteers for the first time. Launched on the 4th of August 2023, the clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.

Oxford to launch UK’s first trials unit dedicated to precision-prevention and early detection studies

18 July 2023

Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.

African Phase I HIV vaccine trial shows encouraging preliminary results

12 July 2023

The multisite Phase I HIV-CORE 006 HIV vaccine clinical trial, run by the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), has concluded successfully.

Drug shows promise for stroke patients with bleeding in brain

4 July 2023

A clinical trial has shown that a drug commonly used for patients with bleeding disorders has the potential to be used to lessen the side effects of blood-thinning drugs for patients who have experienced a stroke.

Rapid weight loss found to be safe and helpful for people with liver disease, Oxford trial reveals

28 June 2023

A clinical trial, led by a team at NDPCHS, has shown that a three-month rapid weight loss programme was not only safe but also effective in reducing the severity of a liver disease called non-alcoholic steatohepatitis (NASH) with liver fibrosis.

Major trials to test effectiveness of cannabidiol on psychosis

16 February 2023

A global study involving three clinical trials will investigate the effectiveness of cannabidiol (CBD) in treating people with psychosis or psychotic symptoms, thanks to a multi-million pound grant to Oxford University.

Oxford spinout trials revolutionary bioelectronic implant to treat incontinence

1 February 2023

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their “smart” bioelectronic implants.

Molnupiravir doesn't reduce COVID-19 hospitalisations in high-risk vaccinated people

3 January 2023

Researchers from the University of Oxford released findings from a clinical trial investigating the effectiveness of the antiviral treatment molnupiravir against COVID-19 – the first treatment tested in the ongoing PANORAMIC trial. In their paper published in The Lancet, they reported that molnupiravir did not reduce hospitalisations or deaths among higher risk, vaccinated adults with COVID-19 in the community.

Oxford’s Ebola vaccine recommended for deployment against Uganda outbreak

18 November 2022

A vaccine developed by the Oxford Vaccine Group’s Prof Teresa Lambe and supported in clinical trials and manufacture scale-up by researchers from the Jenner Institute (Nuffield Department of Medicine) has been recommended for inclusion in a ring vaccination trial to combat a Sudan ebolavirus outbreak in Uganda.

New study shows muscle pain is not due to statins in over 90% of those taking the treatment

30 August 2022

Statin therapies are not the cause of muscle pain in over 90% of those who experience symptoms, according to a new study led by researchers from Oxford Population Health. The results were published today in The Lancet and presented at the European Society of Cardiology Congress.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

29 June 2022

The Oxford Clinical Trials Research Unit at Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMS) played a key role in the Vaccine Response On Off Methotrexate (VROOM) study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Breakthrough in treatment for Dupuytren’s disease

30 April 2022

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

World Malaria Day 2022

25 April 2022

Patient recruitment is on-track in the Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa.

RECOVERY Trial launches in South Africa

13 December 2021

The world’s largest clinical trial investigating treatments for COVID-19 has now launched in South Africa, with the first patient recruited today. This is the fifth country to take part in RECOVERY, joining Nepal, Indonesia, Vietnam, and the United Kingdom.

Search results

Found 91 matches for